Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 19 and 75 years~* Signed informed consent~Exclusion Criteria:~* At screening, SPB ≥ 180mmHg or DBP ≥ 110mmHg or LDL-C \> 250mg/dL or TG ≥ 400mg/dL~* Has a history of hypersensitivity to Angiotensin Ⅱ receptor blocker or HMG-CoA reductase inhibitor or component of this drug~* Has a history of multi-drug allergy

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Irbesartan/Atorvastatin A (Type: EXPERIMENTAL): None
- Irbesartan (Type: ACTIVE_COMPARATOR): None
- Atorvastatin A (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Irbesartan/Atorvastatin B (Type: EXPERIMENTAL): None
- Atorvastatin B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).